Conclusion
The mixing of OXY injection and TXA products for co-administration with IV infusion fluids should be avoided until the exact nature of the interaction and its implications for quality-assured and non-quality-assured products are understood. Further investigation is urgently needed to characterise the underlying mechanisms leading to the observed phenomena and, as appropriate, determine mitigation strategies.